Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the me...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2020-07, Vol.63 (13), p.6648-6676
Hauptverfasser:	Hansen, Joshua D, Correa, Matthew, Nagy, Mark A, Alexander, Matt, Plantevin, Veronique, Grant, Virginia, Whitefield, Brandon, Huang, Dehua, Kercher, Timothy, Harris, Roy, Narla, Rama Krishna, Leisten, Jim, Tang, Yang, Moghaddam, Mehran, Ebinger, Katalin, Piccotti, Joseph, Havens, Courtney G, Cathers, Brian, Carmichael, James, Daniel, Thomas, Vessey, Rupert, Hamann, Lawrence G, Leftheris, Katerina, Mendy, Derek, Baculi, Frans, LeBrun, Laurie A, Khambatta, Gody, Lopez-Girona, Antonia
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!